We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Aptima Mycoplasma genitalium Assay Evaluated

By LabMedica International staff writers
Posted on 12 Oct 2017
Print article
Image: The Aptima Mycoplasma genitalium Assay (Photo courtesy of Hologic).
Image: The Aptima Mycoplasma genitalium Assay (Photo courtesy of Hologic).
Mycoplasma genitalium (MG) frequently causes non-gonococcal urethritis (NGU) in males, and is associated with cervicitis, pelvic inflammatory disease, endometritis and probably infertility.

Nucleic acid amplification tests (NAATs) are the only appropriate diagnostic methods. Many commercially available and particularly laboratory-developed diagnostic polymerase chain reactions (PCRs) have been used.

A large team of scientists working with those at Örebro University (Örebro, Sweden) collected urogenital and extra-genital (only in Denmark) specimens from consecutive attendees at three STD clinics from February 2016 to February 2017. The specimens were tested with the CE/IVD AMG, the research-use-only MG Alt TMA-1 assay, Aptima Combo 2 Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) (CT/NG) assay, and a laboratory-developed TaqMan real-time mgpB qPCR. Resistance-associated mutations were determined by sequencing. Strains of MG and other mycoplasma species in different concentrations were also tested. The CE/IVD AMG the Aptima Combo 2 (CT/NG) assays was performed on Hologic’s Panther system.

In total 5,269 patients were included in the study. The prevalence of MG was 7.2% (382/5269; 4.9%-9.8% in the different countries). The sensitivity of the CE/IVD AMG, MG Alt TMA-1 and mgpB qPCR ranged between 99.13%-100%, 99.13%-100%, and 73.24%-81.60%, respectively, in the countries. The specificity ranged between 99.57%-99.96%, 100%, and 99.69%-100%, respectively. The prevalence of resistance-associated mutations for azithromycin and moxifloxacin was 41.4% (120/290; 17.7%-56.6%) and 6.6% (18/274; 4.1%-10.2%), respectively. Multidrug-resistance was found in all countries (2.7%; 1.1%-4.2%).

The authors concluded that the new CE/IVD Aptima Mycoplasma genitalium assay (Hologic) performed in the fully automated Panther system showed a high clinical sensitivity and specificity and offers a simple, rapid, sensitive and specific MG diagnostics, which can be easily combined with detection of CT, NG and Trichomonas vaginalis. The study was published on September 17, 2017, in the journal Clinical Microbiology and Infection.

Related Links:
Örebro University

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.